Dasatinib synergizes with JSI-124 to inhibit growth and migration and induce apoptosis of malignant human glioma cells

• Main Authors: Premkumar Daniel, Jane Esther, Agostino Naomi, Scialabba Joseph, Pollack Ian
• Format: Article
• Language: English
• Published: Wolters Kluwer Medknow Publications 2010-01-01
• Series: Journal of Carcinogenesis
• Subjects: Apoptosis; dasatinib; glioma; JSI - 124; migration
• Online Access: http://www.carcinogenesis.com/article.asp?issn=1477-3163;year=2010;volume=9;issue=1;spage=7;epage=7;aulast=Premkumar

<b>Background:</b> Src family kinases (SFK) collectively regulate a variety of cellular functions in many cancer types, including proliferation, invasion, motility, survival, differentiation, and angiogenesis. Although Dasatinib (BMS-354825), an ATP-competitive, small molecule tyrosine kinase inhibitor, suppresses the activity of SFKs at nanomolar concentrations, IC50 values for antiproliferative effects in glioma cell lines were well above the clinically achievable range, suggesting the need to interfere with other components of receptor-induced downstream signaling in order to achieve an optimal therapeutic effect.<b> Materials and Methods:</b> The cytotoxic effects of combining Src and STAT3 inhibition on glioma cell lines were evaluated using assays to measure cell proliferation, apoptosis and migration. Western blotting and immunocytochemistry was used to monitor its effects on cell signaling and morphology. <b> Results:</b> Silencing Src and STAT3 expression each partially inhibited cell proliferation and migration. In addition, JSI - 124 significantly enhanced the efficacy of dasatinib in vitro. Combination of dasatinib and JSI - 124 achieved significant inhibition of migration in all cell lines, which correlated with the inhibition of Src and downstream mediators of adhesion (e.g. focal adhesion kinase). Cells exposed to dasatinib and JSI-124 exhibited morphological changes that were consistent with an upstream role for Src in regulating focal adhesion complexes. <b> Conclusions:</b> Targeting the Src and STAT pathways may contribute to the treatment of cancers that demonstrate increased levels of these signaling mediators, including malignant human glioma. Clinical studies in these tumor types are warranted.